Expert Ratings for Mirati Therapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, Mirati Therapeutics (NASDAQ:MRTX) received 4 somewhat bullish and 3 indifferent ratings from analysts. The average 12-month price target is $58.43, representing a 9.17% decrease from the previous average of $64.33.
June 16, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Mirati Therapeutics received mixed ratings from analysts, with an average 12-month price target of $58.43, down 9.17% from the previous average.
The article provides an overview of analyst ratings for Mirati Therapeutics, with a mix of somewhat bullish and indifferent ratings. The average 12-month price target has decreased by 9.17% from the previous average, indicating a potential short-term neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100